JAGUAR HEALTH, INC. Other Comprehensive Income (Loss), Net of Tax
JAGUAR HEALTH, INC. (JAGX) reported Other Comprehensive Income (Loss), Net of Tax of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-19
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $1.00K.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$458.00K.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $7.00K, a 97.28% decline year-over-year.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$134.00K.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for fiscal 2025 was -$411.00K, a 289.40% decline from fiscal 2024.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $217.00K, a 600.00% increase from fiscal 2023.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $31.00K.
- JAGUAR HEALTH, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$680.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-19 | -$457.00K 10-Q · filed 2026-08-19 | -$450.00K derived: sum of 3 quarters · filed 2026-08-19 | -$584.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$458.00K 10-Q · filed 2026-05-20 | -$451.00K derived: sum of 2 quarters · filed 2026-05-20 | -$585.00K derived: sum of 3 quarters · filed 2026-05-20 | -$607.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$127.00K derived: sum of 2 quarters · filed 2026-04-07 | -$149.00K derived: sum of 3 quarters · filed 2026-08-19 | -$411.00K 10-K · filed 2026-04-07 |
| 2025-09-30 | -$134.00K 10-Q · filed 2025-11-14 | -$156.00K derived: sum of 2 quarters · filed 2026-08-19 | -$418.00K 10-Q · filed 2025-11-14 | -$161.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$22.00K 10-Q · filed 2026-08-19 | -$285.00K 10-Q · filed 2026-08-19 | -$27.00K derived: sum of 3 quarters · filed 2026-08-19 | -$191.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$262.00K 10-Q · filed 2026-05-20 | -$5.00K derived: sum of 2 quarters · filed 2026-05-20 | -$169.00K derived: sum of 3 quarters · filed 2026-05-20 | -$263.00K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $93.00K derived: sum of 2 quarters · filed 2026-04-07 | -$1.00K derived: sum of 3 quarters · filed 2026-04-07 | $217.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | -$164.00K 10-Q · filed 2025-11-14 | -$258.00K derived: sum of 2 quarters · filed 2025-11-14 | -$40.00K 10-Q · filed 2025-11-14 | $122.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$94.00K 10-Q · filed 2025-08-14 | $124.00K 10-Q · filed 2025-08-14 | $286.00K derived: sum of 3 quarters · filed 2025-08-14 | $203.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $217.00K 10-Q · filed 2025-05-15 | $380.00K derived: sum of 2 quarters · filed 2025-05-15 | $297.00K derived: sum of 3 quarters · filed 2025-05-15 | $480.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $80.00K derived: sum of 2 quarters · filed 2025-03-31 | $263.00K derived: sum of 3 quarters · filed 2025-03-31 | $31.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$83.00K 10-Q · filed 2024-11-13 | $100.00K derived: sum of 2 quarters · filed 2024-11-13 | -$132.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $183.00K 10-Q · filed 2024-08-13 | -$49.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$232.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$680.00K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |